Celgene (CELG) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
Celgene (CELG) Revlimid Estimates, PT Lifted at Nomura
October 24, 2014 9:48 AM EDTNomura Securities analyst Ian Somaiya reiterated a Buy and Top Pick rating while boosting his price target on Celgene (NASDAQ: CELG) to $136.00 (from $124.00) following results.
Somaiya commented, "We are increasing our Revlimid estimates and TP to $136, from $124, as we see continued strength in Revlimid sales heading... More
Celgene (CELG) Price Target Raised to $134 at Deutsche Bank
October 24, 2014 9:07 AM EDTDeutsche Bank maintained a Buy rating on Celgene (NASDAQ: CELG) and raised its price target to $134.00 (from $115.00). Analyst Robyn Karnauskas said Celgene was emerging as top pick for 2015.
"The focus of the 3Q call was the strong Otezla launch, and the pipeline,... More
